Syngle Therapeutics is focused on developing an immunotherapy for the treatment of Parkinson’s disease. Syngle possesses several antibodies against oligomeric alphasynuclein, the main toxic species in Parkinson pathology.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Brain Science Tools BV.
Syngle Therapeutics Questions
Syngle Therapeutics's website is http://www.syngletherapeutics.com
Syngle Therapeutics's LinkedIn profile is https://www.linkedin.com/company/syngle-therapeutics
Syngle Therapeutics's industry is
Biotechnology Research
Syngle Therapeutics's top competitors are
Crossbeta Biosciences B.v.,
Tno,
Broadreach Global,
Pantarhei Bioscience B.v.,
Tzu Cancer Therapeutics,
Grow - Research Institute For Oncology And Reproduction,
Sourcia,
First Fund,
Proqr Therapeutics,
Brain Science Tools Bv.
Syngle Therapeutics's categories are Biotechnology Research
Syngle Therapeutics's founding year is 2020
